Peter M. Neupert net worth and biography

Peter Neupert Biography and Net Worth

Peter Neupert has served as a member of our board of directors since December 2013. Peter currently serves as a member of the Board of Trustees of Fred Hutch. Peter served as an Operating Partner at Health Evolution Partners, a private equity fund, from February 2012 to July 2014. Prior to joining Health Evolution Partners, Peter served as Corporate Vice President, Health Solutions Group at Microsoft from August 2005 to January 2012, and as the Chief Executive Officer and Chairman of the board of directors of Drugstore.com, which he founded in 1998.

Peter currently serves on the board of directors of Laboratory Corporation of America Holdings, a public clinical laboratory company, and he previously served as a member of the board of directors of NextGen Healthcare, Inc., a public software company, and several private companies. Peter holds an MBA from the Tuck School of Business at Dartmouth College and a BA in Philosophy from Colorado College.

What is Peter M. Neupert's net worth?: The estimated net worth of Peter M. Neupert is at least $1.69 million as of March 10th, 2025. Mr. Neupert owns 224,690 shares of Adaptive Biotechnologies stock worth more than $1,689,669 as of April 2nd. This net worth evaluation does not reflect any other investments that Mr. Neupert may own. Learn More about Peter M. Neupert's net worth.
How do I contact Peter M. Neupert?: The corporate mailing address for Mr. Neupert and other Adaptive Biotechnologies executives is 1551 EASTLAKE AVENUE EAST SUITE 200, SEATTLE WA, 98102. Adaptive Biotechnologies can also be reached via phone at (206) 659-0067 and via email at investors@adaptivebiotech.com. Learn More on Peter M. Neupert's contact information.
Has Peter M. Neupert been buying or selling shares of Adaptive Biotechnologies?: Peter M. Neupert has not been actively trading shares of Adaptive Biotechnologies during the last ninety days. Most recently, Peter M. Neupert sold 10,000 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $7.05, for a transaction totalling $70,500.00. Following the completion of the sale, the director now directly owns 224,690 shares of the company's stock, valued at $1,584,064.50. Learn More on Peter M. Neupert's trading history.
Who are Adaptive Biotechnologies' active insiders?: Adaptive Biotechnologies' insider roster includes R. Adams (COO), Lance Baldo (Insider), Sharon Benzeno (Insider), Chad Cohen (CFO), Egon Durban (Director), David Goel (Director), Michelle Griffin (Director), Robert Hershberg (Director), Francis Lo (Insider), Peter Neupert (Director), Jyoti Palaniappan (SVP), Kyle Piskel (CFO), Chad Robins (CEO), Chad Robins (CEO), Harlan Robins (Insider), Julie Rubinstein (President), and Stacy Taylor (SVP). Learn More on Adaptive Biotechnologies' active insiders.
Are insiders buying or selling shares of Adaptive Biotechnologies?: During the last twelve months, insiders at the sold shares 12 times. They sold a total of 757,849 shares worth more than $6,041,858.67. The most recent insider tranaction occured on March, 24th when insider Harlan S Robins sold 1,698 shares worth more than $15,282.00. Insiders at Adaptive Biotechnologies own 6.2% of the company. Learn More about insider trades at Adaptive Biotechnologies.
Information on this page was last updated on 3/24/2025.

Peter M. Neupert Insider Trading History at Adaptive Biotechnologies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/10/2025	Sell	10,000	$7.05	$70,500.00	224,690

Peter M. Neupert Buying and Selling Activity at Adaptive Biotechnologies

Adaptive Biotechnologies Company Overview

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Today's Range

Now: $7.52

$7.13

$7.63

50 Day Range

MA: $7.91

$6.67

$8.66

2 Week Range

Now: $7.52

$2.28

$9.01

Volume

2,403,291 shs

Average Volume

1,478,476 shs

Market Capitalization

$1.12 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.53